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ABSTRACT 
Background: A significant proportion of autogenous vein grafts fail in the 
long term. Currently, there is no treatment to improve graft patency. 
Objective: This study was designed to assess the effectiveness of eicosapen- 
taenoic acid (EPA) to prevent late failure of an autogenous vein graft and other 
perioperative risk factors affecting long-term patency. 
Methods: A retrospective chart review was performed on grafts of patients 
who underwent infrainguinal bypass surgery using autogenous vein grafts for 
peripheral arterial disease in a lower limb. Patients were stratified by the peri- 
operative use of EPA. The EPA group was those patients who administered EPA 
_>1 time within 3 months of surgery. The non-EPA group was made up of those 
patients who did not administer EPA within 3 months of surgery. Primary, 
assisted primary, and secondary patency rates of the grafts in each group were 
calculated by the Kaplan-Meier method and compared by the log-rank test. To 
evaluate the effect of other perioperative risk factors, a Cox proportional haz- 
ards analysis was performed. 
Results: One hundred sixty-one grafts were analyzed from 159 patients who 
underwent surgery between July 1991 and July 2005. The primary patency rates of 
the EPA and non-EPA groups were 93% and 86%, 89% and 74%, and 83% and 68% 
at 1, 3, and 5 years, respectively. In terms of primary patency, the EPA group was 
significantly better than the non-EPA group (P = 0.042). There was no significant 
difference between the groups in either assisted primary or secondary patency. A
Cox proportional hazard analysis found that the minimum graft diameter and peri- 
operative use of EPA were significant factors for primary patency (P = 0.002 and 
P = 0.004, respectively). Graft diameter was the only significant factor for assisted 
primary and secondary patency (P = 0.021 and P = 0.003, respectively). 
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Conclusion: Although graft diameter was the most important factor for long- 
term patency of infrainguinal vein bypass grafts, the perioperative use of EPA 
significantly improved primary patency among these subjects. (Curr Ther Res 
Clin Exp. 2007;68:161-174) Copyright © 2007 Excerpta Medica, Inc. 
Key words: eicosapentaenoic acid, graftpatency, autogenous vein graft, long- 
term outcome, perioperative use. 
INTRODUCTION 
Use of an autogenous vein is the gold standard for infrainguinal bypass. ~ How- 
ever, 20% to 30% of implanted autogenous vein grafts fail in the long term after 
bypass urgery. 2 The problems that occur between 2and 18 months are usually 
attributed to intimal hyperplasia; thereafter, changes are primarily due to the 
progression of atherosclerosis. 3,4 Accordingly, prevention of intimal hyperplasia 
might improve the long-term patency of autogenous vein grafts. 
Eicosapentaenoic a id (EPA), an agent contained in fish oil, is well known for 
its action against arteriosclerosis by replacing arachidonic acid in the lipo- 
polysaccharides of the cell membrane. 5,6 Clinical and experimental trials have 
suggested antiatherogenic and antithrombotic effects for EPA, including bene- 
fits on lipoprotein metabolism, blood pressure, endothelial function, vascular 
reactivity, inflammation, platelet and fibrinolytic function, cytokine production, 
coagulation, and oxidative stress. 7,s Because these events can influence the 
development of intimal hyperplasia in an implanted autogenous vein graft, oral 
administration of EPA in the perioperative period might prevent late failure of 
autogenous vein grafts. 
The purpose of this study was to assess the effectiveness of perioperative 
EPA on the long-term outcome of autogenous vein bypass for peripheral arterial 
disease, and to elucidate the perioperative risk factors affecting raft patency. 
MATERIALS AND METHODS 
The institutional review board of the Nippon Steel Yawata Memorial Hospital, 
Kitakyushu-City, Japan, approved the study design. 
The clinical records of patients who underwent infrainguinal bypass surgery 
using autogenous vein grafts for peripheral arterial disease in a lower limb were 
reviewed. These records were obtained from the hospital's computer database. 
The grafts were categorized into 2 groups depending on perioperative use of 
EPA. The EPA group started oral EPA (Epadel, Mochida Pharmacuetical Co., Ltd., 
Tokyo, Japan), 900 to 1800 mg, within 2 weeks after bypass surgery and contin- 
ued for >3 months; the non-EPA group did not take EPA within 3 months after 
bypass surgery. The grafts of patients who stopped oral EPA within 3 months 
after surgery, or who started oral EPA >2 weeks after surgery, were excluded. 
Grafts that occluded within 3 months after surgery regardless of continued use 
of EPA from the early postoperative period were included in the EPA group. 
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To elucidate other perioperative risk factors, the following data were noted 
from the charts: age, sex, diagnosed isease requiring bypass surgery, preopera- 
tive complication of diabetes, hypertension, coronary artery disease, stroke, 
hemodialysis, hypercholesterolemia, smoking history (self-reported), medical 
records from treating physicians or laboratory data of preoperative examination, 
operative indication (claudication vs critical imb ischemia), graft orientation (sin- 
gle vein graft vs complex spliced vein graft), distal anastomotic level (popliteal 
artery vs crural artery or foot artery), number of bypass procedures in ipsilateral 
limb (first case vs repeat case), concomitant inflow reconstruction, postoperative 
use of warfarin sodium, antiplatelet therapy (ticlopidine, cilostazol, aspirin, or sar- 
pogrelate hydrogen chloride), statins, postoperative smoking, and graft minimum 
diameter measured on an angiogram taken 2 to 4 weeks after bypass urgery. 
Graft patency was determined objectively by pulsation of the graft, ankle 
brachial pressure index (ABPI), or color Doppler examination at intervals of 
3 months. Investigators were blinded to patient information except with regard 
to the bypass site. Angiography was recommended in cases of disappearance 
of graft pulsation, decline of ABPI to 80% of previous levels, or obvious stenosis 
detected by color Doppler examination. When significant problems leading to 
graft failure were found with angiography, revision surgery was recommended. 
The definition of patency was in accordance with the recommended reporting 
standards of the Ad Hoc Committee on Reporting Standards, Society for Vascu- 
lar Surgery/North American Chapter, International Society for Cardiovascular 
Surgery. 9 Primary patency rate was defined as the uninterrupted uration of 
patency without intervention. Assisted primary patency rate was defined as uninter- 
rupted duration of patency with intervention. Secondary patency rate was defined 
as duration of patency restored to the same conduit after bypass graft occlusion. 
The cutoff for follow-up was at 60 months after initial bypass surgery, with the 
final follow-up undertaken i January 2006. 
Primary, assisted primary, and secondary patency rates were calculated by 
the Kaplan-Meier method and evaluated by a log-rank test. In addition, a Cox 
proportional hazard analysis with properties having P < 0.3 in a univariate 
analysis was performed to determine the relative risk of each property. P < 0.05 
was considered to be significant. 
RESULTS 
One hundred seventy-six patients underwent infrainguinal bypass from July 
1991 to July 2005:179 limbs and 181 autogenous vein grafts. Because the pur- 
pose of this study was to elucidate the risk factors for late graft failure (ie, 
graft thrombosis or stenosis requiring some revision surgery to maintain its 
patency and which occurred over 30 days after the initial bypass surgery), we 
excluded 2 grafts in 2 patients who died within 30 days of surgery and 18 grafts 
that occluded or required revision surgery to maintain graft patency within 
30 days after the initial surgery. None of these excluded patients had taken EPA. 
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One hundred fifty-six patients with 161 grafts in 159 limbs were enrolled. At the 
final analysis, 75 grafts from 74 patients and 82 grafts from 78 patients were in 
the EPA and non-EPA groups, respectively. 
Baseline Characteristics 
The mean age of the 156 enrolled patients (116 men and 40 women) was 
67.5 years (range, 26-88 years). Indications for bypass urgery were arteriosclero- 
sis obliterans (143 [92%]), Buerger's disease (10 [6%]), remote vascular trauma 
(2 [1%]), popliteal artery aneurysm (1 [1%]), acute arterial occlusion (1 [1%]), and 
chronic arterial occlusion due to an unknown cause (4 [3%]). Infrainguinal 
bypass was performed for disabling claudication in 56 limbs and for critical 
limb ischemia in 103 limbs. The 161 grafts used for bypass surgery comprised 
125 (78%) single grafts (91 reversed, 23 in situ, and 11 nonreversed vein) and 
36 (22%) spliced vein grafts. The distal landing artery was the popliteal artery 
in 78 patients (51 above the knee and 27 below the knee) and a more distal 
artery in 83 (44 posterior tibial artery, 16 peroneal artery, 8 anterior tibial 
artery, 6 tibioperoneal trunk, and 9 pedis dorsal artery). Concomitant recon- 
struction for inflow improvement was performed in 25 (16%) bypasses, and 19 
(12%) bypasses were repeat surgeries. Existing preoperative comorbidities 
included type 2 diabetes mellitus (75 [48%]), hypertension (97 [62%]), ischemic 
heart disease (47 [30%]), stroke (34 [22%]), and renal failure while undergoing 
hemodialysis (21 [13%]). Of the 154 patients with a measured preoperative 
serum cholesterol level, 22 (14%) had hypercholesterolemia. One hundred and 
fifteen (74%) patients had a history of smoking. 
Effect o f  EPA on Graft Patency Rate 
Perioperative properties of the EPA and non-EPA groups are summarized in 
Table I. There were no significant differences between the groups, except with 
regard to renal failure with hemodialysis (EPA, 4 [5%] vs non-EPA, 17 [21%]). 
Primary, assisted primary, and secondary graft patency rates for each 
group are shown in Figure 1. The cumulative primary patency rates of the 
EPA and non-EPA groups were 93% and 86%, 89% and 74%, and 83% and 68% 
at 12, 36, and 60 months, respectively. The EPA group was significantly better 
than the non-EPA group in terms of primary patency (P = 0.042). The assisted 
primary patency rates of the EPA and non-EPA groups were 94% and 87%, 91% 
and 83%, and 84% and 80% at 12, 36, and 60 months, respectively, and the sec- 
ondary patency rates of the EPA and non-EPA group were 94% and 87%, 91% 
and 83%, and 87% and 80% at 12, 36, and 60 months, respectively. There was 
no statistically significant difference between the groups in either assisted 
primary or secondary graft patency rate. 
Effect of Other Factors on Graft Patency Rate 
Based on univariate analysis, the history of ischemic heart disease, concomi- 
tant inflow procedures, and graft minimum diameter were significant risk fac- 
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Table I. Perioperative parameters in patients who underwent infrainguinal bypass sur- 
gery using autogenous grafts for peripheral arterial disease in a lower limb. 
Patients were categorized into 2 groups depending on postoperative use of 
eicosapentaenoic acid (EPA). Data are no. (%) except where otherwise noted. 
EPA* Non-EPA t 
Properties (n = 75) (n = 82) P 
Age, mean (SD), y 68.5 (11.4) 67.0 (9.3) 0.409~ 
>70 38 (51) 41 (50) 1.000 
<70 37 (49) 41 (50) 
Sex 0.996 
Male 57 (76) 59 (72) 
Female 18 (24) 23 (28) 
Reason for surgery 1.000 
Critical limb ischemia 50 (67) 54 (66) 
Claudication 25 (33) 28 (34) 
Type 2 diabetes mellitus 0.406 
Yes 34 (45) 42 (51) 
No 41 (55) 40 (49) 
Hypertension 0.I 47 
Yes 52 (69) 45 (55) 
No 23 (31) 37 (45) 
Ischemic heart disease 0.734 
Yes 22 (29) 25 (30) 
No 53 (71) 5 7 (70) 
Stroke 0.328 
Yes 15 (20) 21 (26) 
No 60 (80) 61 (74) 
Hypercholesterolemia§ 1.000 
Yes 11 (15) 12 (15) 
No 64 (85) 68 (85) 
Renal failure 0.047 
Yes 4 (5) 17 (21) 
No 71 (gs) 6S (79) 
Smoking history 0.685 
Yes 58 (77) 58 (71) 
No 17 (23) 24 (29) 
Diagnosis 0.669 
ASO 69 (92) 70 (85) 
Others 6 (8) 12 (15) 
Distal anastomosis 1.000 
Popliteal 35 (47) 41 (50) 
More distal 40 (53) 41 (50) 
(continued) 
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Table I. (Continued) 
EPA* Non-EPAt 
Properties (n = 75) (n = 82) 
Vein graft 0.568 
Single 55 (73) 66 (80) 
Spliced 20 (27) 16 (20) 
Inflow operation 0.712 
Yes 14 (19) 10 (12) 
No 61 (81) 72 (88) 
Redo surgery 0.526 
Yes 11 (15) 8 (10) 
No 64 (85) 74 (90) 
Graft diameter, mean (SD)§ 3.5 (0.9) 3.6 (1.0) 0.424 
<3 mm 26 (36) 18 (23) 0.0605 
>3 mm 47 (64) 61 (77) 
Warfarin 0.873 
Yes 37 (49) 4 7 (5 7) 
No 38 (51) 35 (43) 
Antiplatelet drug 0.828 
Yes 47 (63) 59 (72) 
No 28 (37) 23 (28) 
Statin§ 0.526 
Yes 12 (16) 8 (12) 
No 63 (84) 73 (88) 
Continued smoking§ 1.000 
Yes 12 (16) 18 (22) 
No 62 (83) 64 (78) 
ASO = arteriosclerosis obliterans. 
*Started oral EPA 900 to 1800 mg/d within 2 weeks of surgery and continued for _>3 months. 
tDid not administer EPA within 3 months after surgery. 
~ 2 test. 
N values less than total are the result of missing data. 
tors for primary patency (P = 0.039, P = 0.015, and P = 0.011, respectively). Graft 
minimum diameter was the only significant factor for assisted primary and sec- 
ondary patency rates (P = 0.005 and P = 0.004, respectively) (Table If). Vein 
grafts with a minimum diameter visualized on postoperat ive angiography of 
<3.0 mm were significantly worse than larger vein grafts in terms of patency 
0Figure 2). The number of patients in the EPA group with a vein graft size 
<3.0 mm was 26 versus 18 in the non-EPA group. Patients in the EPA group 
166 
-0 -  EPA 
-0 -  Non-EPA 
100 4 
80-  == 
=.. ~ 60- 
~ v  
.-> 
_~ 4o- 
E 
= 20- U 
~ 0  
S. Mii et aL 
0 I I I I I 
0 12 24 36 48 60 
r -  
¢U 
.~ cu 
me,p  
E 
U 
100 
80-  
60-  
40-  
20-  
Months After Surgery 
0 I I I I I 
0 12 24 36 48 60 
100 4 
80-  
e,, 
=.. ~ 60- 
_~ 40- 
E 
20- 
U 
Months After Surgery 
0 I I I I I 
0 12 24 36 48 60 
Months After Surgery 
Figure 1. Primary (A), assisted primary (B), and secondary (C) patency rates of auto- 
genous vein grafts in patients who underwent infrainguinal bypass surgery 
for peripheral arterial disease in a lower limb. Patients were categorized 
into 2 groups depending on postoperative use of eicosapentaenoic acid 
(EPA). 
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Table II. P Values of log-rank test to determine association between patient proper- 
ties and graft patency in patients who underwent infrainguinal bypass sur- 
gery using autogenous grafts for peripheral arterial disease in a lower limb. 
Patency 
Assisted 
Properties Primary* Primaryt Secondary* 
Age 0.987 0.860 0.961 
Sex 0.696 0.688 0.512 
Operative indication 0.269 0.304 0.387 
History 
Diabetes mellitus 0.985 0.997 0.816 
Hypertension 0.613 0.967 0.814 
Ischemic heart disease 0.039 0.415 0.340 
Stroke 0.684 0.244 0.117 
Hypercholesterolemia 0.5 70 0.836 0.775 
Renal failure 0.612 0.241 0.211 
Smoking 0.669 0.816 0.897 
Diagnosis 0.821 0.349 0.308 
Distal anastomosis 0.278 0.161 0.107 
Used vein graft 0.681 0.593 0.681 
Concomitant inflow operation 0.015 0.324 0.287 
Repeat surgery 0.624 0.483 0.896 
Graft diameter 0.011 0.005 0.004 
Concomitant medication 
Warfarin 0.4 76 0.933 0.926 
Antiplatelet drug 0.715 0.801 0.706 
Stati n 0.724 0.851 0.816 
Continued smoking 0.779 0.859 0.760 
Eicosapentaenoic acid 0.042 0.320 0.213 
*Uninterrupted uration of patency without intervention. 
tUninterrupted uration of patency with intervention. 
~Duration of patency restored to the same conduit after bypass graft occlusion. 
had better patency after 3 months than those in the non-EPA group, but the 
difference was not statistically significant. 
Cox Proport ional  Hazards Analysis 
Using factors for which P < 0.3 by univariate analysis, a Cox proportional haz- 
ard analysis was performed. For primary patency rate, graft minimum diameter 
and perioperative use of EPA were significant factors (P = 0.002 and P = 0.004, 
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Figure 2. Primary (A), assisted primary (B), and secondary (C) patency rates of auto- 
genous vein grafts in large (>3 mm diameter) and small (<3 mm) veins in 
patients who underwent infrainguinal bypass surgery using autogenous 
grafts for peripheral arterial disease in a lower limb. 
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Table III. Results of a Cox proportional hazards analysis using factors that had 
P < 0.3 by univariate analysis. 
Parameters P Risk Ratio 95% CI 
Primary patency* 
Ischemic heart disease 0.226 1.661 0.730-3.775 
Inflow operation 0.060 2.467 0.964-6.311 
Distal anastomosis 0.797 1.108 0.50 7-2.4 22 
Graft minimum diameter 0.002 0.250 0.105-0.596 
EPA, perioperative use 0.004 0.282 0.120-0.665 
Assisted primary patencyt 
Renal failure 0.277 1.857 0.609-5.662 
Stroke 0.241 0.480 0.141-1.637 
Distal anastomosis 0.341 1.513 0.645-3.550 
Graft minimum diameter 0.021 0.361 0.152-0.859 
Secondary patency~ 
Renal failure 0.443 1.61 4 0.487-5.348 
Stroke 0.157 0.343 0.078-1.506 
Inflow operation 0.857 1.1 24 0.317-3.978 
Distal anastomosis 0.358 1.572 0.599-4.125 
Graft minimum diameter 0.003 0.204 0.072-0.577 
EPA, perioperative use 0.077 0.396 0.142-1.105 
EPA = eicosapentaenoic acid. 
*Uninterrupted uration of patency without intervention. 
t Uninterrupted uration of patency with intervention. 
Duration of patency restored to the same conduit after bypass graft occlusion. 
respectively). For assisted primary and secondary graft patency rates, graft 
diameter was the only significant factor (P = 0.021 and P = 0.003, respectively) 
~Table II0. 
DISCUSSION 
Graft failure with thrombosis can occur at any time after the first postoperative 
month. It is usually due to the development of a flow-reducing lesion within the 
bypass graft or its inflow or outflow tract, and intimal hyperplasia is a promi- 
nent cause of failure and graft thrombosis. When significant intimal hyperplasia 
occurs in an infrainguinal graft, it usually leads to graft failure 2 to 18 months 
after the operation; thereafter, progression of the atherosclerotic disease pro- 
cess involving the inflow or outflow tract of the arterial reconstruction be- 
comes the predominant cause of failure and graft thrombosis. 3,4 Accordingly, in- 
hibition of intimal hyperplasia nd the progression of atherosclerotic disease 
can improve graft patency. Although various drugs have been shown to inhibit 
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intimal hyperplasia in experimental models ,  1°-17 no drugs have been proven 
effective in preventing late graft failure in a clinical setting. To improve the long- 
term patency of infrainguinal bypass with an autogenous vein graft, many stud- 
ies, mainly using antiplatelet or anticoagulant agents, have been performed. 
Although aspirin and dipyridamole were used in several studies, the results 
were controversial, is-2° A positive result with ticlopidine on the 2-year patency 
of saphenous vein bypass grafts in the leg was reported by Becquemin. 21Sarac 
et a122 indicated that concomitant use of warfarin and aspirin was superior to 
aspirin monotherapy in patients at high risk of graft failure. The benefits of oral 
anticoagulant agents have been reported elsewhere. 23,24 The results from a ret- 
rospective analysis of 172 consecutive patients 25 suggested the efficacy of 
statins in improving secondary patency (P < 0.02), but not primary patency. 
Although the randomized, controlled study by Eritsland et a126 reported that 
dietary supplementation with n-3 fatty acids reduced the incidence of vein graft 
occlusion in 610 patients undergoing coronary artery bypass grafting (P < 
0.004), this has not been reported in the field of leg revascularization. 
In the present study, the EPA group was significant in terms of the primary 
patency of the autogenous vein graft in the leg. Basic and clinical research as 
indicated that EPA has a positive effect on atherosclerosis as well as intimal 
hyperplasia. In experimental models, it was found that fish oil including EPA 
was associated with reduced intimal hyperplasia in injured artery and vein 
grafts. 27-29 Within several weeks after bypass grafting, remodeling of the im- 
planted vein graft occurs under the influence of the arterial environment. 3° In- 
timal hyperplasia develops in the early period after vein grafting; therefore, the 
anti-atherogenic and antithrombotic actions of EPA 7,8 must function most effec- 
tively during this time. In addition, replacement of arachidonic acid with EPA in 
the lipopolysaccharides of the cell membrane during this early period may lead 
to inhibition of intimal hyperplasia nd atherosclerotic change at a later time. 
The difference between the EPA and non-EPA groups in primary patency be- 
came more evident 6 months after bypass urgery. Possible reasons for the lack 
of significant differences in the assisted primary and secondary patency rates 
were that the observation period after revision surgery was shorter, revised 
lesions were localized, and >50% of patients took EPA after revision surgery. 
Size, 31-36 quality, 33-36 and length of vein graft 36-38 have been indicated as risk 
factors affecting the long-term patency of vein grafts. In the present study, 
though neither quality nor length was evaluated, graft diameter was the most 
significant risk factor for primary, assisted primary, and secondary patency. 
Most of the grafts that failed (primary patency) within 6 months after bypass 
surgery were categorized as smaller vein grafts of <3 mm in diameter, while, as 
mentioned previously, most of the grafts that failed after 6 months were from 
the non-EPA group. This suggests that the effectiveness of EPA might be more 
prominent at later stages and not as obvious in the early stage. 
This retrospective study design is a limitation and thus significant caution 
should be given in respect o its interpretation. There was no rule determining 
171 
CURRENT THERAPEUTIC RESEARCH 
about which patients were chosen to receive EPA after bypass surgery while 
others were not. Thus, there might be potential selection bias even at the start- 
ing point of the use of EPA. Data on the use of EPA was gained retrospectively 
from patients' records and might be incomplete and subject to recall bias. The 
small sample size might have been a limitation to the study. It was also impos- 
sible to evaluate patient compliance and duration of therapy. Continued use of 
EPA for >3 months after bypass surgery could not be followed-up in all cases 
and, conversely, a few patients in the non-EPA group started oral EPA >3 months 
after surgery. Large, multicenter, randomized, prospective trials are needed to 
demonstrate the true clinical efficacy of EPA. 
CONCLUSION 
This small retrospective study suggests the possibility of an inhibitory effect of 
EPA on late graft occlusion of autogenous veins in the leg. Although graft diam- 
eter was the most important factor for long-term patency of infrainguinal vein 
bypass grafts, the perioperative use of EPA significantly improved primary 
patency among these subjects. 
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